<< Altus Pharmaceuticals reaffirms plan to submit NDA for Trizytek | Exercise increases brain growth factor and receptors, prevents stem cell drop in middle age >>

Celprogen introduces in vivo model for human glioblastoma

Published on November 18, 2008 at 3:54 AM · No Comments

Celprogen Inc. has announced that they have successfully validated an in vivo model system for testing efficacy of cancer drugs and also novel drug candidates for Human Glioblastoma.

This in vivo model system has been validated within United States research facilities for testing novel drug candidates against Human Glioblastoma.

Celprogen's in vivo model system would enable scientists all over the world to test their potential drug candidates against Human Brain Cancer (GBM), which is one of the hardest human cancers to treat and diagnose.

Celprogen has established a Drug Discovery program to provide drug efficacy testing services to major Pharmaceutical firms for their potential drugs against Human Glioblastoma. The other in vivo cancer model systems in the pipe line at Celprogen are: breast cancer, prostate cancer, liver cancer, colon cancer, lung cancer and pancreatic cancer that are scheduled to be released as early as the beginning of second quarter 2009. These in vivo cancer model systems are being generated from already established Celprogen's Cancer Stem Cells.

http://www.celprogen.com

9b631840-62fe-47f8-8b6d-69fc3e62483a|0|.0

Posted in: Pharmaceutical News

Tags: Brain, Brain Cancer, Breast Cancer, Cancer, Colon Cancer, Glioblastoma, Liver Cancer, Lung Cancer, Pancreatic Cancer, Prostate Cancer

Related posts

Basic Yellow 1 dye extends lifespan in healthy nematodes, slows Alzheimer's disease-like pathology in wormsBasic Yellow 1, a dye used in neuroscience laboratories around the world to detect damaged protein i...
Low levels of pre-treatment radiation do not risk radiotherapy efficacy in prostate, lung cancer patientsScientists from the Barbara Ann Karmanos Cancer Institute in Detroit will present data that suggests...
New type of radiation reduces GI side effects but does not improve survival rate in prostate cancer patientsA new British review of existing research suggests that while a newer type of radiation for the trea...
Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsiaZeria Pharmaceutical announced today positive results of their Japanese Phase III study of Z-338 (ac...
'Forgotten' cells in brain cancerGlioblastoma is a guileful enemy. While most of the brain tumor can often be removed surgically, in ...
The National Fragile X Foundation awards $100,000 grant for study of minocycline in FXS childrenThe National Fragile X Foundation has awarded a translational research seed grant of $100,000 to Dr....
Angiogenesis inhibitors, study points to limitations, solutionsA new generation of cancer drugs designed to starve tumors of their blood supply - called "angiogene...
microRNAs may help predict survival in liver cancerTiny molecules that help cells regulate which proteins they make might one day help doctors predict ...
Johns Hopkins to participate in 1000 Genomes ProjectResearchers at the McKusick-Nathans Institute of Genetic Medicine (IGM) at Johns Hopkins will join o...
Extension of embryo screening will help reduce serious illnessA fertility watchdog in Britain, the Human Fertilisation and Embryology Authority (HFEA), has given ...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.